tbuckley/cabot-search huggingface dataset:
P2.05-049 Radical Treated NSCLC Radiotherapy Patients: A Prospective Study of Toxicities and Outcomes
Authors: Nathaniel Hatton, Philip Mcloone, Kathryn Graham, Jonathan Hicks, Graeme Lumsden, Jennifer Macphee, Anila Patibandla, Stephen Harrow
Journal: Journal of Thoracic Oncology (2017)
Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome
Authors: Chantal Sellier, Ronald A.M. Buijsen, Fang He, Sam Natla, Laura Jung, Philippe Tropel, Angeline Gaucherot, Hugues Jacobs, Hamid Meziane, Alexandre Vincent, Marie-France Champy, Tania Sorg, Guillaume Pavlovic, Marie Wattenhofer-Donze, Marie-Christine Birling, Mustapha Oulad-Abdelghani, Pascal Eberling, Frank Ruffenach, Mathilde Joint, Mathieu Anheim, Veronica Martinez-Cerdeno, Flora Tassone, Rob Willemsen, Renate K. Hukema, Stéphane Viville, Cecile Martinat, Peter K. Todd, Nicolas Charlet-Berguerand
Journal: Neuron (2017)

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by a limited expansion of CGG repeats in the 5′ UTR of FMR1. Two mechanisms are proposed to cause FXTAS: RNA gain-of-function, where CGG RNA sequesters specific proteins, and translation of CGG repeats into a polyglycine-containing protein, FMRpolyG. Here we developed transgenic mice expressing CGG repeat RNA with or without FMRpolyG. Expression of FMRpolyG is pathogenic, while the sole expression of CGG RNA is not. FMRpolyG interacts with the nuclear lamina protein LAP2β and disorganizes the nuclear lamina architecture in neurons differentiated from FXTAS iPS cells. Finally, expression of LAP2β rescues neuronal death induced by FMRpolyG. Overall, these results suggest that translation of expanded CGG repeats into FMRpolyG alters nuclear lamina architecture and drives pathogenesis in FXTAS.
P1.02-006 Interlaboratory Variation in Molecular Testing (EGFR, KRAS and ALK) in Stage IV Non-Squamous Non-Small Cell Lung Cancer in the Netherlands in 2013
Authors: Chantal Kuijpers, Lucy Overbeek, Sandra Rotteveel, René Van Ommen, Koos Koole, Henk-Jan Van Slooten, Michel Van Den Heuvel, Ronald Damhuis, Stefan Willems
Journal: Journal of Thoracic Oncology (2017)
Comparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and Physicians
Authors: Michael Kelley
Journal: Annals of Internal Medicine (2017)

Letters3 January 2017Comparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and PhysiciansMichael Kelley, MDMichael Kelley, MDFrom ProVita, Abu Dhabi, United Arab Emirates.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0551 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I read Mafi and colleagues' article (1) with interest. It comes as little surprise that, with regard to treating such simple conditions as head colds, primary care providers and APCs provide equal amounts of low-quality health care. It doesn't take much training or skill to diagnose a self-limited viral infection. Doing the right thing doesn't require professional training—it requires the will to stick to one's professional guns and refuse to hand out a placebo regimen of antibiotics (or radiographs). So, perhaps this study should be titled “Both Primary Care Providers and APCs Fail the Test of Giving ...Reference1. Mafi JN, Wee CC, Davis RB, Landon BE. Comparing use of low-value health care services among U.S. advanced practice clinicians and physicians. Ann Intern Med. 2016;165:237-44. [PMID: 27322541]. doi:10.7326/M15-2152 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From ProVita, Abu Dhabi, United Arab Emirates.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L16-0551. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and Physicians John N. Mafi , Christina C. Wee , Roger B. Davis , and Bruce E. Landon Comparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and Physicians John N. Mafi and Bruce E. Landon Comparing Use of Low-Value Health Care Services Among U.S. Advanced Practice Clinicians and Physicians Pierre-Géraud Claret , Xavier Bobbia , and Jean Emmanuel de La Coussaye Metrics 3 January 2017Volume 166, Issue 1Page: 76KeywordsAntibioticsDisclosureHealth careHealth care providersMedical servicesPatientsPrimary careResidency ePublished: 3 January 2017 Issue Published: 3 January 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
S77 Modulatory effects of rheumatoid arthritis IGG on neutrophil activation: a potential role in RA-ILD
Authors: AA Khawaja, C Pericleous, VM Ripoll, HL Booth, V Holmes, T Mikolasch, I Giles, JC Porter
Journal: Thorax (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is an autoimmune rheumatic disease (ARD) characterised by circulating autoantibodies, including anti-citrullinated protein antibodies (ACPA). Many RA patients have extra-articular disease, including ∼10% with interstitial lung disease (ILD). Risk factors for RA-ILD include: male sex; age; smoking history and ACPA positivity. <h3>Hypothesis</h3> We propose that RA-IgG, including ACPA, modulate neutrophil functions including: generation of reactive oxygen species (ROS), neutrophil adhesion and generation of neutrophil extracellular traps (NETs) that may contribute to joint and extra-articular tissue damage, including ILD. <h3>Methods</h3> Neutrophils and IgG were isolated from RA patients or healthy controls (HC). Bronchoalveolar lavage (BAL) was performed on ILD patients and controls underdoing bronchoscopy for other reasons. ROS production was measured using an enzymatic assay to assess hydrogen peroxide (H2O2) generation. Neutrophil integrins were quantified by flow cytometry. Effects of purified IgG upon neutrophil adhesion to immobilised fibrinogen (Mac-1/aMß2-dependent) and fibronectin (VLA-4/a4ß1-dependent) were determined using a fluorescent adhesion assay. NETosis was measured using a novel capture ELISA. <h3>Results</h3> We demonstrated increased NETs in the BAL of patients with active ILD (n = 3; ARD-ILD) compared to those with inactive disease (n = 2; IPF and ARD-ILD) or controls (n = 1; CLL). In addition, we showed binding of RA-IgG to control neutrophils, which increased with neutrophil activation. Stimulation of HC (n = 12) and RA (n = 7) neutrophils with PMA produced similar rates of H2O2 generation (p = 0.9939). Exposure of HC neutrophils to RA-IgG (n = 9) however, increased H2O2 production compared to HC-IgG (n = 9) (p &lt; 0.0001), which was not blocked by FcR blockade. RA-IgG also enhanced PMA-stimulated adhesion of HC neutrophils to fibrinogen (p = 0.0028) and fibronectin (p = 0.0024), which was inhibited by aMß2 or ß1 integrin blockade respectively. RA-IgG increased both spontaneous (p = 0.0248) and PMA-induced (p = 0.0200) NETosis of HC neutrophils compared to HC-IgG. Immunofluorescence studies demonstrate that aMß2 activation induces NETosis. Further examination found that NETosis could be suppressed by p38 MAPK inhibition (p = 0.0034). <h3>Conclusion</h3> We have shown that RA-IgG modulates several aspects of neutrophil activation and function. In addition, we found increased neutrophil activation in the lungs of patients with active ARD-ILD. Further work is underway to evaluate the contribution of these processes to the pathogenesis of RA-ILD.
Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection
Authors: Yumiko Nagao, Nao Nishida, Licht Toyo-oka, Atsushi Kawaguchi, Antonio Amoroso, Marco Carrozzo, Michio Sata, Masashi Mizokami, Katsushi Tokunaga, Yasuhito Tanaka
Journal: Clinical Gastroenterology and Hepatology (2017)

There is a close relationship between hepatitis C virus (HCV) infection and lichen planus, a chronic inflammatory mucocutaneous disease. We performed a genome-wide association study (GWAS) to identify genetic variants associated with HCV-related lichen planus.We conducted a GWAS of 261 patients with HCV infection treated at a tertiary medical center in Japan from October 2007 through January 2013; a total of 71 had lichen planus and 190 had normal oral mucosa. We validated our findings in a GWAS of 38 patients with HCV-associated lichen planus and 7 HCV-infected patients with normal oral mucosa treated at a medical center in Italy.Single-nucleotide polymorphisms in NRP2 (rs884000) and IGFBP4 (rs538399) were associated with risk of HCV-associated lichen planus (P < 1 × 10-4). We also found an association between a single-nucleotide polymorphism in the HLA-DR/DQ genes (rs9461799) and susceptibility to HCV-associated lichen planus. The odds ratios for the minor alleles of rs884000, rs538399, and rs9461799 were 3.25 (95% confidence interval, 1.95-5.41), 0.40 (95% confidence interval, 0.25-0.63), and 2.15 (95% confidence interval, 1.41-3.28), respectively.In a GWAS of Japanese patients with HCV infection, we replicated associations between previously reported polymorphisms in HLA class II genes and risk for lichen planus. We also identified single-nucleotide polymorphisms in NRP2 and IGFBP4 loci that increase and reduce risk of lichen planus, respectively. These genetic variants might be used to identify patients with HCV infection who are at risk for lichen planus.
P1.02-023 Application of an Amplicon-Based NGS Strategy in the Molecular Diagnosis of NSCLC: Comparable Performance with FISH and ARMS-PCR
Authors: Dongmei Lin, Lei Li, Dongfeng Niu, Yang Yu, Lixin Zhou, Lianju Gao, Xuehong Meng, Zhi Jiang, Jiafu Ji
Journal: Journal of Thoracic Oncology (2017)
Adipocyte Dynamics and Reversible Metabolic Syndrome in Mice with an Inducible Adipocyte-Specific Deletion of the Insulin Receptor
Authors: Masaji Sakaguchi, Shiho Fujisaka, Weikang Cai, Jonathon N. Winnay, Masahiro Konishi, Brian T. O'Neill, Mengyao Li, Rubén García-Martín, Hirokazu Takahashi, Jiang Hu, Rohit N. Kulkarni, C. Ronald Kahn
Journal: Cell Metabolism (2017)
P219 Evaluation of individual activity descriptors of the mrc dyspnoea scale: do they add up?
Authors: J Yorke, M Khan, J Vestbo, D Singh, PJ Jones
Journal: Thorax (2016)

<h3>Introduction</h3> The MRC dyspnoea scale consists of five grades that contain of a description of more than one activity. The comparability of these components is not known. This study aimed to examine the performance of individual descriptions of each MRC grade. <h3>Methods</h3> Phase I: cognitive debriefing with COPD patients was conducted to elicit their understanding of each activity (10 items) of the five MRC grades. Phase II: COPD patients completed the MRC scale (grades 1–4) and a MRC-Exploded (MRC-Ex) version consisting of 10-items, each representing one MRC activity. Each item used a 4-point response scale (0 ‘not at all’ to 4 ‘all of the time’). Rasch analysis was used to assess the pattern of MRC-Ex item severity (logit) to assess the appropriateness of combining individual activity descriptors into single MRC grades. <h3>Results</h3> 36 patients participated in cognitive debriefing. Key issues identified: MRC 1: unclear what constituted ‘strenuous exercise’ and does not represent mild severity and MRC 5: ‘too breathless to leave the house’ viewed as “much worse than being breathless with dressing”. 203 patients completed Phase II (mean age 64.7 SD 7.5 years, GOLD: 1:14% 2:41% 3:25% 4:7%). The easiest item to affirm was ‘walking up a slight hill’ (logit −2.76) and “too breathless to leave the house” was the most difficult (logit 3.42) (Table 1). MRC components in grade 5 are not of equivalent severity - at least 2 logits apart. <h3>Conclusions</h3> This study highlight the importance of context when using the MRC. Grade 1 “strenuous exercise” is unlikely to yield a reliable response from patients diagnosed with COPD. Secondly, if data collection is taking place outside of the home then it is pointless to ask respondents if they are too breathless to leave the house; on the other hand, if studying patients who may require palliative care services, that might well be relevant. For contexts where it would be relevant, we suggest separating Grade 5 components: “leave the house” and “dressing/undressing”.
Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer.
Authors: T. J. George, H. Liu, L. V. Duckworth, J. E. Sullivan, J. Dong, C. Liu, L. H. Dang, K. Slentz-Kesler, C. J. Allegra
Journal: Journal of Clinical Oncology (2011)

3598 Background: First-line treatment of mCRC commonly utilizes FF+B. No reliable markers exist to predict clinical response to therapy. High-throughput genomic tumor screening may be of value to determine a genetic signature which predicts response to FF+B. Methods: All mCRC patients (pts) treated with first-line FF+B between 2000 and 2008 were independently reviewed for RECIST response. Formalin fixed paraffin embedded (FFPE) tumor samples underwent single blinded histopathologist review, microdissection with RNA extraction and hybridization to a CRC-specific microarray. Bioinformatic analysis was used to determine gene expression differences (GED) between responders (R) vs. nonresponders (NR). Principle component analysis (PCA) and hierarchical clustering (HC) were used to determine genomic relationships between R, NR, primary tumor (P) and metastases (mets). Results: 25 unique pts with 54 tumor specimens were processed. 88% (48/54) of FFPE had adequate RNA for analysis. More recent FFPE samples were associated with more successful RNA retrieval (p=0.053). FFPE age <36mo = 100% retrieval vs. 88% at 36-72mo vs. 60% >72mo. Under or over-GED were significant (sig) between P and site of mets including liver (79 genes; range -8.4 to +5.5 fold GED; p<0.05), lung (205 genes; range -6.1 to +110 fold GED; p<0.05), and ovary (117 genes; range -75 to +7 fold GED; p<0.05). There were no differences between R/NR in met site, Ki67% (median 53%), or microvessel density (MVD). HC identified a stringent gene listing (p<0.01; fold change >2) for R vs. NR. There were no differences between R/NR in primary MVD, but Ki67% was sig higher in R (66 vs. 35%; p=0.05). HC identified a stringent gene listing (p<0.01; fold change >2) for R vs. NR. Gene pathways involved in R/NR analysis include vascular development, angiogenesis regulation, and apoptosis. Representative GED products and ontology pathways are being analyzed. Conclusions: CRC microarray processing can be successfully conducted on historical FFPE, particularly if <72 mo old. Genomic profiling of P and mets confirm sig GED between met sites, R and NR, with confirmation testing of gene products ongoing. High Ki67 % in primary tumor may also predict response to FF+B.
PLGA-PLL-Peg-Tf-Based Targeted Nanoparticles Drug Delivery System Enhance Antitumor Efficacy Via Intrinsic Apoptosis Pathway
Authors: Wen Bao, Ran Liu, Baoan Chen, Fei Wang, Haijun Zhang, Guohua Xia, Xue Wu, Kun Zhao, Xiaoyu Li
Journal: Blood (2015)
P192 Improving outcomes for patients with respiratory failure using protocol based care plans for NIV (non-invasive ventilation) and HFNO (high flow nasal oxygen)
Authors: AW Werpachowska, RO O’Leary, MK Kimberley, FA Archer, CM Maquire, ID Du Rand
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Respiratory failure is a common clinical problem and a number of treatment options are available. NIV is an established treatment for hypercapenic type two respiratory failure (RF). High Flow Nasal Oxygen (HFNO) is an alternative to standard oxygen or CPAP, and its use in hypoxemic patients has been growing. NHS adheres to evidence based guidance and protocols to improve the safety, quality and consistency of care. We developed and implemented local guidance and protocols for managing respiratory failure with HFNO and NIV in a District General Hospital. <h3>Methods</h3> A retrospective analysis of data from inpatient type 2 respiratory failure and NIV prior and post BTS Guideline based local protocol implementation was collected. Analysis was done to assess adherence to protocol and compare quality care and outcomes with data prior to implementation. For type 1 respiratory failure a literature review was done, evidence appraised and local guidance and protocol for HFNO developed and a pilot study conducted. <h3>Results</h3> Since introduction of NIV proforma: NIV more frequently initiated in appropriate setting. Compliance with recommended ABG monitoring improved from 85% to 100%. Documentation of escalation plans improved from 50% to 100% (Figure 1). HFNO was successfully implemented and commenced in our Trust over 10 weeks. All patients on HFNO tolerated therapy. Prevented ITU admission in 80% of cases selected for monitored ward based care of respiratory failure. <h3>Conclusions</h3> In the present study, we showed how to safely implement evidence based local guidance and protocol based care plans for managing type 1 and 2 respiratory failure in a DGH to improve quality of care, improve adherence to BTS guidelines, reduce in-hospital mortality and prevent ITU admission. We believe the guideline and protocol supported the on-call teams to identify and safely manage respiratory failure. We continue to evaluate the service.
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Authors: Giancarlo Agnelli, Paolo Prandoni, Maria Gabriella Santamaria, Paola Bagatella, Alfonso Iorio, Mario Bazzan, Marco Moia, Giuliana Guazzaloca, Adriano Bertoldi, Cristina Tomasi, Gianluigi Scannapieco, Alessandra Ascani, Sabina Villalta, Michela Frulla, Laura Mosena, Antonio Girolami, Antonella Vaccarino, Adriano Alatri, Gualtiero Palareti, Mario Marchesi, Giovanni Battista Ambrosio, Roberto Parisi, Silvia Doria, Luigi Steidl, Fabio Ambrosini, Mauro Silingardi, Angelo Ghirarduzzi, Ido Iori, Walter Ageno
Journal: New England Journal of Medicine (2001)

In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy. Whether this benefit persists after anticoagulant therapy is discontinued is controversial.
Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL
Authors: Eva Lengfelder, Francesco Lo-Coco, Pau Montesinos, David Grimwade, Lionel Ades, Bhuvan Kishore, Maria Pagoni, Safaa M. Ramadan, Massimo Breccia, Alexandra Holowiecka, Anne Pradel, Maria Cristina Sauerland, Pierre Fenaux, Miguel Angel Sanz
Journal: Blood (2010)
Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.
Authors: Ivana N Micallef, Patrick Stiff, Edward Stadtmauer, Brian J. Bolwell, Sachin Marulkar, Frank J Hsu, John F. DiPersio
Journal: Blood (2009)
Imatinib-induced apoptosis could be enhanced by Triptolide in Imatinib-resistant chronic myeloid leukemia cell line through down-regulation of HIF-1αand Nrf2
Authors: Bing Xu, Feili Chen, Yuejian Liu, Shiyun Wang, Rongwei Li, Huijuan Dong, Jie Zha
Journal: Blood (2013)
18f-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). A Preliminary Retrospective Analysis of Children's Oncology Group (COG) AHOD0031
Authors: Steve Y Cho, Kathleen M McCarten, Lu Chen, Debra L Friedman, Suzanne L Wolden, Kathryn Karolczuk, Cindy L Schwartz, Kara M Kelly
Journal: Blood (2012)
OA08.05 Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis
Authors: Akihiro Tamiya, Motohiro Tamiya, Takashi Nishihara, Takayuki Shiroyama, Keiko Nakao, Taisuke Tsuji, Naoko Takeuchi, Shun-Ichi Isa, Naoki Omachi, Norio Okamoto, Hidekazu Suzuki, Ayano Iwazaki, Kimie Imai, Tomonori Hirashima, Shinji Atagi
Journal: Journal of Thoracic Oncology (2017)
P1.02-038 Over- Expression of Epidermal Growth Factor Receptor 1 (EGFR1) Gene in Serum of Adenocarcinoma Lung at a Tertiary Level Centre in North India
Authors: Ashraf Ansari, Anant Mohan, Mirza Masroor, Alpana Saxena, Kalpana Luthra, Karan Madan, Vijay Hadda, G. Khilnani, Randeep Guleria
Journal: Journal of Thoracic Oncology (2017)
P1.07-042 Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios Predict Prognosis in Early-Stage Resected Small-Cell Lung Cancer Patients
Authors: Virag Hollosi, Judit Moldvay, Matyas Bendek, Gyula Ostoros, Balazs Hegedus, Balazs Dome, Glen Weiss, Zoltan Lohinai
Journal: Journal of Thoracic Oncology (2017)
P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC
Authors: Ronan Kelly, Leora Horn, James Chih-Hsin Yang, Dae Ho Lee, Bhardwaj Desai, Tanya Fleege, Fei Jie, Srinivasu Poondru, Anne Keating, Debbie Whitcomb, Tosei Murase, Koichi Uegaki, Kouji Aoyama, Kazuhiko Nakagawa
Journal: Journal of Thoracic Oncology (2017)
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response
Authors: Quteba Ebrahem, Reda Z. Mahfouz, Lisa Durkin, Mikkael A. Sekeres, Anjali S. Advani, Hetty E. Carraway, Sudipto Mukherjee, Betty K. Hamilton, Aaron T. Gerds, Ronald Sobecks, Frederic J. Reu, Eric D. Hsi, Jaroslaw P. Maciejewski, Yogenthiran Saunthararajah
Journal: Blood (2015)
Value‐based care in hepatology
Authors: Mario Strazzabosco, John I. Allen, Elizabeth O. Teisberg
Journal: Hepatology (2017)

The migration from legacy fee-for-service reimbursement to payments linked to high-value health care is accelerating in the United States because of new legislation and redesign of payments from the Centers for Medicare and Medicaid Services. Because patients with chronic diseases account for substantial use of health care resources, payers and health systems are focusing on maximizing the value of care for these patients. Because chronic liver diseases impose a major health burden worldwide affecting the health and lives of many individuals and families as well as substantial costs for individuals and payers, hepatologists must understand how they can improve their practices. Hepatologists practice a high-intensity cognitive subspecialty, using complex and costly procedures and medications. High-value patient care requires multidisciplinary coordination, labor-intensive support for critically ill patients, and effective chronic disease management. Under current fee-for-service reimbursement, patient values, medical success, and financial success can all be misaligned. Many current attempts to link health outcomes to reimbursement are based on compliance with process measures, with less emphasis on outcomes that matter most to patients, thus slowing transformation to higher-value team-based care. Outcome measures that reflect the entire cycle of care are needed to assist both clinicians and administrators in improving the quality and value of care. A comprehensive set of outcome measures for liver diseases is not currently available. Numerous researchers now are attempting to fill this gap by devising and testing outcome indicators and patient-reported outcomes for the major liver conditions. These indicators will provide tools to implement a value-based approach for patients with chronic liver diseases to compare results and value of care between referral centers, to perform health technology assessment, and to guide decision-making processes for health authorities. This review sets the groundwork for implementing a value-based, patient-centered approach to chronic liver diseases within a health system. (Hepatology 2017;65:1749-1755).